Background Image Background Image

We're a non-profit dedicated to making medications affordable for everyone in America

Imagine you need a drug that costs $50,000. With a $5,000 deductible and $50 copay, that's too much. So you skip treatment.

Now imagine Congress cuts the price of all drugs in half. This means less research for new cures, but at least it helps you - right?

Not so fast. Your drug costs $25,000 now, but your deductible is still $5,000. That's because insurance reform is the key to making drugs affordable.

Here’s the thing. No one should go broke, skip their medications, or even die because they can’t pay their out-of-pocket costs

So how
do we fix this?

Our goal is to ensure that all Americans can afford the treatments they need and guarantee that our country continues to get good value from investment in new medicines


Eliminate out-of-pocket costs


Expand insurance to everyone


Ensure—through government regulation—that all drugs go generic

Unlike drugs, nothing about healthcare services gets less expensive over time

The costs of surgeries and doctor visits are always rising, much like rent

Cost of healthcare over time

But what America spends on new drugs is like a mortgage—an investment, not an expense

Once we have paid off a drug’s mortgage, it goes generic, society owns it, and its cost is forever low. We believe drugs that don’t go generic on time should be required to do so.

Cost of healthcare over time

Why this matters

As old drugs go generic, America can invest in mortgages for new ones, improving our health and saving money on hospitalizations. And with proper insurance with low or no out-of-pocket costs, all patients will be able to afford the treatments they need.

Media and Resources


When Simpler isn't Better

A case for generalizing cost-effectiveness math to avoid undervaluing medicines


CMS Rule to Lower Maximum Out-of-Pocket Costs by $400 Will Help Patients, More Reductions Needed

NPLB welcomes key provisions in the CMS Notice of Benefit and Payment Parameters for 2022 Final Rule


NPLB Applauds Growing Momentum for Insurance Reforms that Lower Out-of-Pocket Costs for Patients

Prioritizing reforms such as drug pricing and access that help patients is essential


Patient Out-of-Pocket Costs Continue to Climb While Insurers are Covering Fewer Drugs

Despite Reductions in Pharmaceutical Manufacturer Net Drug Prices


How To Kill The Conversation That Makes Innovation Possible

A short analysis

Timmerman Report

A Glimpse into a Price-Controlled Future

What would it look like if some of the H.R. 3 bill's provisions were enacted?


NPLB Applauds President’s Expansion of Affordable Healthcare

More Americans Helped, More Still to be Done


Booker-Sanders-Harris drug affordability bureau could be brilliant

Or, it could completely collapse our industry

Timmerman Report

Insurance Reform, Not Executive Orders, is the Best Tool to Protect US Patients

The President's executive orders do nothing to lower out-of-pocket costs


Patients will be the losers as Pelosi's plan to control drug prices nearly strikes out

Two strikes and a home run


A quantum of innovation and the incentives to match

What's the smallest increment of medical innovation that is worth its cost to society?

Timmerman Report

If Trikafta Isn't Good Enough for ICER, What Drug Is?

A life-changing drug for cystic fibrosis patients is deemed "not worth it


We need a Public Domain Day to highlight when drugs go off patent

Let's celebrate when drug patents expire


5 Million Black and Hispanic people may lose their coverage because of the pandemic

Join us in making drugs affordable for every American

  • Insurance for all
  • No more out-of-pocket costs
  • All drugs should go generic